Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
83,427 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 2, 2026 | Independence Blue Cross | Trilaciclib (Cosela)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-134 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Trigger Point InjectionsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-017 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Triamcinolone Acetonide ER Injectable (Zilretta)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-097 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatments for Complex Regional Pain Syndrome (CRPS)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-026 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Varicose Veins of the Lower Extremities and Perforator Vein IncompetencePayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-001 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic AgentsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-016 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Obstructive Sleep Apnea (OSA) and Primary Snoring in AdultsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA05-047 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Obesity and Bariatric Surgery for Treatment of Morbid ObesityPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-051 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Medical and Surgical ComplicationsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-050 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Trastuzumab (Herceptin) and Related Biosimilars, Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-018 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA05-006 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Transcatheter Cardiac Valve ProceduresPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-027 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Transcatheter Arterial Chemoembolization (TACE) of Hepatic MalignanciesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA07-040 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tracheostomy Care SuppliesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA05-034 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Total Parenteral Nutrition (TPN) / Intradialytic Parenteral Nutrition (IDPN)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-008 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Toripalimab-tpzi (Loqtorzi)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-170 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous InjectionPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-045 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tisotumab vedotin-tftv (Tivdak)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-141 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tislelizumab-jsgr (Tevimbra)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-173 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tildrakizumab-asmn (Ilumya)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-098 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Therapeutic Transcranial Magnetic Stimulation (TMS)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA07-035 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Therapeutic ShoesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA05-020 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, and AntiepilepticsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA06-029 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tezepelumab-ekko (Tezspire)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-144 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Teprotumumab (Tepezza)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-115 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Teplizumab-mzwv (Tzield)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-157 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Telisotuzumab vedotin-tllv (Emrelis)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-040 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Telehealth ServicesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA00-036 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Teclistamab-cqyv (Tecvayli)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-156 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tebentafusp-tebn (Kimmtrak)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-143 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tarlatamab-dlle (Imdelltra for intravenous usePayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-176 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tango Home Health Care Services ManagementPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA00-054 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Talquetamab-tgvs (Talvey)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-166 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tafasitamab-cxix (Monjuvi)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-138 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Sutimlimab-jome (Enjaymo)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-145 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical Treatments of Athletic PubalgiaPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-093 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical Treatment of NailsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-036 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical Procedures of the Eyelid and BrowPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-047 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-004 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Surgery for GynecomastiaPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-110 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA10-008 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Steroid-Eluting Sinus Stents and ImplantsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-107 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Stem-Cell Therapy/Platelet-Rich Plasma for Orthopedic Applications and Platelet-Rich Plasma/Platelet-Derived Growth Factor for Wound Healing and Other Miscellaneous Non-Orthopedic ConditionsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA07-008 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | STAT Laboratory Tests Performed in the Outpatient Hospital Setting for Health Maintenance Organization (HMO) and Point-of-Service (POS) ProductsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA00-021 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Standing FramesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA05-055 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spinal OrthosesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA05-030 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spinal Decompression with Interspinous and Interlaminar DevicesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-048 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Spesolimab-sbzo (Spevigo)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-155 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Speech TherapyPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA10-007 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Speech and Non-Speech Generating DevicesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA05-003 | New policy |
|---|